Christopher Karim

Christopher Karim is a highly experienced senior scientist with a robust background in cell biology and project leadership, currently serving at Cerus since April 2023. Previously, Christopher held multiple positions at Nurix Therapeutics from March 2016 to April 2023, where responsibilities included co-leading a STAT6 targeted protein degradation project. Prior roles at Pfizer involved developing processes for isolating and analyzing tumor-infiltrating lymphocytes, while at Novartis, Christopher designed in vitro testing protocols for global oncology projects. Early career experiences include contributions to programming solutions at Deltagen, developing monoclonal antibodies at BD Pharmingen, and leading quality control testing at Microgenics. Educational qualifications include a Bachelor of Science in Biological Sciences from the University of California, Davis, and a Master of Business Administration in Technology Management from the John Sperling School of Business & Technology.